01 nov: Selskabsmeddelelse nr. 9/2018 - Årsregnskabsmeddelelse, FY 2017/1..
01 nov: Selskabsmeddelelse nr. 10/2018 - Årsrapport 2017/18 og Corporate ..
01-11-2018 08:34:01

Coloplast delivers solid full-year result and 8% growth for the sixth quarter running

Relateret indhold
11 jan - 
Fredagens aktier: Ambu endte i toppen i svagt negativt ..
11 jan - 
Aktier/middag: Danske Bank klarer skærene i afdæmpet ma..
11 jan - 
Aktier/åbning: William Demant topper i grøn fredagsstar..
Relateret debat
29 dec - 
@nohope Der har vaeret tale om to former for afstemning..
29 dec - 
En oldefar der i en periode har været medlem af DNSAP e..
29 dec - 
@tommycarstensen Tak for dine svar. Jeg har arbejdet me..

Coloplast delivered 8% organic revenue growth in the fourth quarter of the 2017/18 financial year and 8% full-year organic revenue growth as well as a 31% EBIT margin. The company is guiding for ~8% organic revenue growth in 2018/19.

Coloplast delivered 8% organic revenue growth in the fourth quarter of its financial year, with reported revenue in DKK up by 6% to DKK 4,234m. Full-year organic revenue growth was also at 8%, while reported revenue in DKK was up by 6% to DKK 16,449m. While lifted by acquisitions, revenue growth measured in DKK was adversely affected by 4% due to currency developments, especially USD and ARS depreciating against DKK.

Relative to the 7% organic growth rates of the past three years, the full-year revenue growth marks a shift in momentum and an acceleration of growth in a market otherwise growing by 4-5%. Accelerating growth was indeed Coloplast’s goal when revising its long-term guidance in November 2017 with the ambition of increasing investments and accelerating growth during the period to 2019/2020 and growing at the upper end of the 7-9% range.

Full-year EBIT amounted to DKK 5,091m, a 1% increase in DKK, for an EBIT margin of 31%, compared to 32% in 2016/17. When measured at constant exchange rates and adjusted for the DKK 90m one-off revenue adjustment related to Veterans Affairs, EBIT was up by 4%, for an EBIT margin of 31% against 33% last year. The EBIT performance is in line with the company guidance and reflects an increase in innovation, sales, and marketing investments across all product categories.

  • “We’re delivering a strong fourth quarter performance at 8% revenue growth for the sixth quarter running, and we’re delivering highly satisfactory full-year results with growth across all regions. Even though 2017/18 was a year of investing for Coloplast, we’re still delivering solid results and we continue to grow at double the market rate. Obviously, I’m quite pleased with that,” said Coloplast CEO Lars Rasmussen.

The business areas produced the following full-year organic growth rates: Ostomy Care 9%, Continence Care 8%, Interventional Urology 10% and Wound & Skin Care 3%. A comprehensive pricing reform in Greece adversely affected the full-year growth performance in the Wound Care business.

Looking at sales by geographies, the European markets contributed 5% growth to FY sales, Other developed markets, driven mainly by the USA, delivered 11% revenue growth, while Emerging Markets provided a 14% increase.

  • “We’re seeing solid growth across our business areas, driven not least by our product launches and commercial investments. We will continue to invest up to 2% of revenue in innovation, sales, and marketing in 2018/19, so we can continue to develop and provide innovative products such as SenSura® Mio Concave. This new product portfolio has been very well received, and it is now available and eligible for reimbursement in ten countries. 2018/19 will be another year of investing, and in the first quarter we are launching SenSura® Mio Baby and SenSura® Mio Kids, designed specifically for premature babies and children up to 4 years,” said Mr Rasmussen.

Through the SenSura® Mio Baby and SenSura® Mio Kids portfolios, Coloplast sets a new standard for paediatric ostomy care products. The two new categories are scheduled for launch in all core markets within the next 12 months.

Financial guidance 2018/19

Coloplast is guiding for ~8% organic revenue growth at constant exchange rates. Reported growth in DKK forecast at 8-9%. EBIT margin of 30-31% expected at constant exchange rates with a reported EBIT margin of ~31% in DKK. The EBIT margin forecast reflects additional investments of up to 2% of revenue for innovation and sales and marketing purposes.

CONTACTS

Lina Danstrup

Senior Media Relations Manager, Corporate Communications

+45 49 11 26 07

dklina@coloplast.com

Ellen Bjurgert

Vice President, Investor Relations

+45 49 11 33 76

dkebj@coloplast.com

Financial highlights and key ratios

 DKKm

2017/18

2016/17

 

Change

 

2017/18

Q4

2016/17

Q4

Change

Revenue 16,449 15,528 6%   4,234 3,980 6%
EBIT 5,091 5,024 1%   1,415 1,319 7%
EBIT margin (at constant exchange rates) 31% 33%

(adjusted for VA)

    33% 34%  
EBIT margin (in DKK) 31% 32%     33% 33%  
Profit for the period 3,845 3,797 1%   1,039 1,010 3%

Sales performance by business area

 DKKm

2017/2018

 

2016/2017

Organic growth

Reported growth

Ostomy Care 6,643 6,291 9% 6%
Continence Care 5,943 5,543 8% 7%
Interventional Urology 1,740 1,641 10% 6%
Wound & Skin Care 2,140 2,143 3% 0%
Other matters   (90)   1%

Revenue

16,449

15,528

8%

6%

 (DKKm)

2017/2018

Q4

2016/2017

Q4

Organic growth

Reported growth

Ostomy Care 1,700 1,597 9% 6%
Continence Care 1,520 1,424 7% 7%
Interventional Urology 432 390 10% 11%
Wound & Skin Care 582 569 4% 2%

Revenue

4,234

3,980

8%

6%

Financial guidance for 2017/18

 

Guidance for 2018/19

Guidance for 2018/19 (DKK)

Sales growth

~8% (organic) 8-9%

EBIT margin

30-31% (at constant exchange rates) ~31%

Capital expenditure

- ~750m

Tax rate

- ~23%

Attachment

logo.png

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

DSV/Exane: Anbefalingen løftes efter købstilbud på rival

17-01-2019 10:12:08
Transport- og logistikkoncernen DSV har fået løftet anbefalingen til "outperform" fra "neutral" af Exane BNP Paribas.Kursmålet lyder fortsat på 600 kr., viser data fra Bloomberg News.Onsdag kom det frem, at DSV har budt rundt regnet 26,5 mia. kr. for den schweiziske transportkoncern Panalpina, hvor bestyrelsen nu overvejer mulighederne.DSV-aktien falder 0,5 pct. til 497 kr. torsdag efter en stigni..

Aktier/tendens: Chr. Hansen i fokus efter regnskabsskuffelse

17-01-2019 08:32:35
Chr. Hansen kommer i fokus fra aktieåbningen herhjemme torsdag, efter at ingredienskoncernen fra morgenstunden har præsenteret tal for første kvartal af det forskudte regnskabsår 2018/19. Både omsætningen og indtjeningen ramte under analytikernes forventninger.Overordnet ventes markederne i Europa torsdag at åbne med en lille pil ned, efter historien om, at de amerikanske myndigheder efterforsker ..

MHI Vestas-rival sender 10 MW-mølle på markedet - NY

16-01-2019 09:26:16
MHI Vestas' største rival, Siemens Gamesa, er nu klar til at følge i hælene på det dansk-japanske selskab med en havvindmølle med en kapacitet på 10 megawatt (MW).Onsdag morgen løfter selskabet sløret for nylanceringen, som vil blive installeret som prototype i år og være klar til installation i stor stil i 2022.Med lanceringen følger Siemens Gamesa i hælene på MHI Vestas, der i september 2018 opg..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Pandora/Sydbank: Signet-tal er skidt nyt - men ingen stor overraskelse
2
Stor britisk bagerkæde har afdækket massiv svindel
3
Aktier/tendens: Chr. Hansen i fokus efter regnskabsskuffelse
4
GE rejser kæmpemølle i Holland til sommer
5
Aktier/middag: Chr. Hansen vender på en tallerken i grønt marked - NY

Relaterede aktiekurser

Coloplast B A/S 609,80 0,9% Stigning i aktiekurs

Køb- og salgssignaler

  • Trend
  • Pengemaskinen

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
17. januar 2019 22:33:34
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190108.3 - EUROWEB7 - 2019-01-17 22:33:34 - 2019-01-17 22:33:34 - 1 - Website: OKAY